Minapharm is one of Egypt's oldest homegrown drugmakers, built around biological medicines rather than simple generics. Its 2025 numbers tell a sharp story: sales grew, but profit collapsed. Full nameMinapharm Pharmaceuticals Tickers / exchangeMIPH — Egyptian Exchange (EGX) Headquarters10th of Ramadan City, Sharqia, Egypt SectorPharmaceuticals / biotechnology EmployeesNot published in available sources Market valueNot published in available sources Yearly salesEGP 6,438.18m (US$122.9m) — FY2025 Net profitEGP 40.22m (US$0.77m) — FY2025 Net margin0.6% (our calculation) Return on equityNot published in available sources Price-to-earningsNot published in available sources Dividend yieldNot published in …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Not ready to buy? Try Company Intelligence free for 14 days →
Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →